Cancer Stem Cells in HCC Hepatocellular carcinoma (HCC) is driven in part by a subpopulation of cancer stem cells (CSCs) - tumor cells with stem-like properties that can self-renew, resist treatment, and seed new tumor growth. Targeting CSCs is a promising but challenging therapeutic strategy.
Metabolic Reprogramming in Cancer Cancer cells dramatically alter their metabolism to support rapid growth. While the Warburg effect (glucose fermentation) is the most famous metabolic change, many cancers also show increased dependence on glutamine metabolism. Glutamine is converted by the enzyme Glutaminase 1 (GLS1) into glutamate, which fuels multiple biosynthetic and energy-generating pathways.
GLS1 as a Potential Oncogene GLS1 and its splice variant GAC (glutaminase C) have been found to be overexpressed in various cancers. The study hypothesized that GLS1 overexpression in HCC plays a specific role in maintaining cancer stem cell identity - beyond simply providing metabolic fuel.
Study Objective The researchers aimed to characterize GLS1 expression in HCC, determine whether the GAC isoform specifically is prognostically relevant, and dissect the mechanistic link between GLS1 activity, reactive oxygen species (ROS), and Wnt/beta-catenin signaling in cancer stem cells.
Expression in Patient Samples GLS1 and GAC isoform expression was assessed in HCC tumor tissue and matched non-tumor liver tissue from patient cohorts. TCGA and GEO datasets were used alongside clinical samples to determine whether GLS1 overexpression correlates with survival outcomes.
Prognostic Analysis Kaplan-Meier survival analysis was performed stratifying HCC patients by GAC expression levels, testing whether high GAC expression is associated with shorter overall survival and recurrence-free survival.
CRISPR/Cas9 Knockout The researchers used CRISPR/Cas9 genome editing to completely knock out GLS1 in HCC cell lines, creating isogenic cell lines that differ only in GLS1 status. This allowed unambiguous attribution of phenotypic changes to GLS1 loss.
Cancer Stem Cell Assays Stemness was measured using sphere formation assays (ability to grow as three-dimensional spheres without attachment), flow cytometry for stem cell surface markers (CD44, CD133, EpCAM), and in vivo tumor initiation assays in immunodeficient mice.
GLS1 is Upregulated in HCC GLS1 was significantly upregulated in HCC tumor tissue compared to adjacent non-tumor liver across multiple datasets. Importantly, the GAC isoform showed particularly strong differential expression and its high level was associated with significantly worse patient prognosis.
GLS1 Knockout Reduces Stemness CRISPR-mediated deletion of GLS1 in HCC cell lines substantially reduced sphere formation capacity, decreased expression of stem cell markers (CD44, CD133), and reduced the proportion of cells with stem-like phenotypes - demonstrating that GLS1 activity is required to maintain the stem cell state.
In Vivo Tumorigenicity GLS1 knockout HCC cells showed markedly reduced ability to form tumors when transplanted into immunodeficient mice. Fewer and smaller tumors formed from knockout cells compared to controls, confirming that GLS1 supports the tumor-initiating capacity that is a defining feature of cancer stem cells.
Rescue Experiments Re-introduction of GLS1 into knockout cells partially rescued sphere formation and tumorigenicity, confirming that the observed effects are specifically due to GLS1 loss rather than off-target CRISPR effects.
GLS1 Regulates ROS Levels Glutamine metabolism through GLS1 generates glutamate, which is a precursor for glutathione synthesis - the cell's primary antioxidant. GLS1 activity therefore controls cellular reactive oxygen species (ROS) levels by sustaining antioxidant capacity. When GLS1 is knocked out, ROS levels rise.
ROS Activates Wnt/Beta-Catenin The elevated ROS resulting from GLS1 loss might seem paradoxical (higher ROS being bad for stem cells), but the key mechanism is that moderate ROS activates Wnt/beta-catenin signaling. This pathway is a master regulator of stem cell self-renewal across many tissue types.
The GLS1-ROS-Wnt Axis Interestingly, the researchers found that GLS1 overexpression in cancer cells maintains an optimal ROS window - not too high, not too low - that supports Wnt activation. This 'Goldilocks' ROS level is precisely regulated by GLS1 activity through its influence on glutathione production.
Beta-Catenin Nuclear Translocation Active Wnt signaling results in beta-catenin entering the cell nucleus and activating stem cell genes. GLS1 knockout reduced nuclear beta-catenin accumulation, while GLS1 overexpression increased it - directly linking glutamine metabolism to stem cell transcriptional programs.
GLS1 as a Drug Target Several GLS1 inhibitors have been developed and are in clinical trials for various cancers. The most advanced is CB-839 (telaglenastat), which has shown activity in multiple cancer types. The findings from this study provide rationale for testing GLS1 inhibitors in HCC patients, particularly those with high GAC expression.
Combination with Standard Therapy If GLS1 inhibition reduces the cancer stem cell compartment while standard therapies kill the bulk tumor, combining GLS1 inhibitors with sorafenib or lenvatinib could prevent the stem cell-driven relapse that frequently occurs after initial treatment response.
Biomarker-Driven Patient Selection Since GAC expression strongly predicts poor prognosis, HCC patients with high GAC tumors could be specifically selected for GLS1 inhibitor-containing regimens - a precision oncology approach that could improve the benefit-to-risk ratio.
Targeting Wnt Signaling The Wnt/beta-catenin pathway has been a longstanding therapeutic target in HCC, but direct Wnt inhibitors have had toxicity issues. Indirectly modulating Wnt activity through GLS1 inhibition - which normalizes the ROS environment - could be a less toxic alternative strategy.
Patient Stratification Criteria The specific threshold of GAC expression that optimally identifies patients likely to respond to GLS1 inhibition needs prospective clinical validation. Standardized assays for clinical measurement of GAC would facilitate this.
Metabolic Compensation Cancer cells are metabolically flexible and may compensate for GLS1 loss by upregulating alternative energy sources. Understanding which compensatory mechanisms arise after GLS1 inhibition will be critical for designing rational combination therapies that prevent resistance.
Immune Interactions GLS1 inhibition affects not only tumor cells but also immune cells in the tumor microenvironment, as lymphocytes are highly dependent on glutamine metabolism. How GLS1 inhibition affects anti-tumor immune responses in HCC deserves dedicated investigation.
Etiology-Specific Context HCC arises from multiple etiologies (HBV, HCV, alcohol, NAFLD). Whether GLS1 dependence and its downstream mechanisms differ across etiological contexts could determine whether GLS1 inhibition is broadly applicable or best suited for specific HCC subtypes.